High-resolution genotyping of Lymphogranuloma Venereum (LGV) strains of Chlamydia trachomatis in London using multi-locus VNTR analysis-ompA genotyping (MLVA-ompA).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 04 01 2021
accepted: 22 06 2021
entrez: 8 7 2021
pubmed: 9 7 2021
medline: 18 11 2021
Statut: epublish

Résumé

Lymphogranuloma venereum (LGV) is caused by Chlamydia trachomatis strains with ompA genotypes L1 to L3. An LGV epidemic associated with the L2b genotype has emerged in the past few decades amongst men who have sex with men (MSM). C. trachomatis genotypes can be discriminated by outer membrane protein A gene (ompA) sequencing, however this method has limited resolution. This study employed a high-resolution genotyping method, namely, multi-locus tandem repeat (VNTR) analysis with ompA sequencing (MLVA-ompA), to assess the distribution of LGV MLVA-ompA genotypes amongst individuals attending genitourinary medicine (GUM) clinics in London. Clinical specimens were collected from individuals attending eight London-based GUM clinics. Specimens that tested positive for C. trachomatis by commercial nucleic acid amplification test (NAAT) were confirmed as LGV by pmpH real-time PCR. LGV-positive DNA extracts were subsequently genotyped using MLVA-ompA. Two hundred and thirty DNA extracts were confirmed as LGV, and 162 (70%) yielded complete MLVA-ompA genotypes. Six LGV MLVA-ompA genotypes were identified: 1.9.2b-L2, 1.9.3b-L2b, 1.9.2b-L2b, 1.9.2b-L2b/D, 1.4a.2b-L2b, and 5.9.2b-L1. The following LGV ompA genotypes were identified (in descending order of abundance): L2, L2b, L2b/D, and L1. Eight ompA sequences with the hybrid L2b/D profile were detected. The hybrid sequence was identical to the ompA of a recombinant L2b/D strain detected in Portugal in 2017. The L2 ompA genotype was found to predominate in the London study population. The study detected an unusual hybrid L2b/D ompA profile that was previously reported in Portugal. We recommend further monitoring and surveillance of LGV strains within the UK population.

Sections du résumé

BACKGROUND
Lymphogranuloma venereum (LGV) is caused by Chlamydia trachomatis strains with ompA genotypes L1 to L3. An LGV epidemic associated with the L2b genotype has emerged in the past few decades amongst men who have sex with men (MSM). C. trachomatis genotypes can be discriminated by outer membrane protein A gene (ompA) sequencing, however this method has limited resolution. This study employed a high-resolution genotyping method, namely, multi-locus tandem repeat (VNTR) analysis with ompA sequencing (MLVA-ompA), to assess the distribution of LGV MLVA-ompA genotypes amongst individuals attending genitourinary medicine (GUM) clinics in London.
METHODS
Clinical specimens were collected from individuals attending eight London-based GUM clinics. Specimens that tested positive for C. trachomatis by commercial nucleic acid amplification test (NAAT) were confirmed as LGV by pmpH real-time PCR. LGV-positive DNA extracts were subsequently genotyped using MLVA-ompA.
RESULTS
Two hundred and thirty DNA extracts were confirmed as LGV, and 162 (70%) yielded complete MLVA-ompA genotypes. Six LGV MLVA-ompA genotypes were identified: 1.9.2b-L2, 1.9.3b-L2b, 1.9.2b-L2b, 1.9.2b-L2b/D, 1.4a.2b-L2b, and 5.9.2b-L1. The following LGV ompA genotypes were identified (in descending order of abundance): L2, L2b, L2b/D, and L1. Eight ompA sequences with the hybrid L2b/D profile were detected. The hybrid sequence was identical to the ompA of a recombinant L2b/D strain detected in Portugal in 2017.
CONCLUSIONS
The L2 ompA genotype was found to predominate in the London study population. The study detected an unusual hybrid L2b/D ompA profile that was previously reported in Portugal. We recommend further monitoring and surveillance of LGV strains within the UK population.

Identifiants

pubmed: 34237111
doi: 10.1371/journal.pone.0254233
pii: PONE-D-21-00203
pmc: PMC8266103
doi:

Substances chimiques

Bacterial Outer Membrane Proteins 0
OMPA outer membrane proteins 149024-69-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0254233

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Infect Immun. 2006 Jan;74(1):578-85
pubmed: 16369014
J Infect Chemother. 2014 Oct;20(10):656-9
pubmed: 25066435
Ned Tijdschr Geneeskd. 2004 Feb 28;148(9):441-2
pubmed: 15038207
BMC Infect Dis. 2011 Mar 14;11:63
pubmed: 21401939
Clin Infect Dis. 2004 Oct 1;39(7):996-1003
pubmed: 15472852
Sex Transm Dis. 2007 Jul;34(7):451-5
pubmed: 17075436
Infect Immun. 2010 Jun;78(6):2544-53
pubmed: 20308297
PLoS One. 2012;7(2):e31538
pubmed: 22363667
Euro Surveill. 2005 Jan 27;10(1):E050127.5
pubmed: 16556955
Sex Transm Infect. 2020 Mar;96(2):137-142
pubmed: 31235527
Genome Res. 2013 May;23(5):855-66
pubmed: 23525359
J Clin Microbiol. 1988 Nov;26(11):2465-6
pubmed: 3069867
Clin Microbiol Infect. 2014 Mar;20(3):219-25
pubmed: 23730727
CMAJ. 2005 Jun 21;172(13):1674-6
pubmed: 15928239
J Clin Microbiol. 1994 Feb;32(2):528-30
pubmed: 8150967
PLoS One. 2017 Sep 25;12(9):e0185059
pubmed: 28945766
J Clin Microbiol. 2007 Mar;45(3):1029-31
pubmed: 17251405
Biol Direct. 2011 May 26;6:28
pubmed: 21615910
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1821-1828
pubmed: 31243838
J Immunol. 2009 Jun 15;182(12):8063-70
pubmed: 19494332
Emerg Infect Dis. 2005 Jul;11(7):1090-2
pubmed: 16022786
Clin Microbiol Infect. 2008 Jul;14(7):644-52
pubmed: 18558936
Microb Genom. 2019 Nov;5(11):
pubmed: 31697227
PLoS One. 2015 May 12;10(5):e0126145
pubmed: 25965545
Emerg Infect Dis. 2016 Nov;22(11):1945-1947
pubmed: 27767927
Clin Infect Dis. 2007 Jan 1;44(1):26-32
pubmed: 17143811
J Clin Microbiol. 2017 Jun;55(6):1968-1969
pubmed: 28404675
J Clin Microbiol. 2007 May;45(5):1410-4
pubmed: 17329456
J Infect Dis. 1992 Aug;166(2):383-92
pubmed: 1634810
Emerg Infect Dis. 2005 Nov;11(11):1787-8
pubmed: 16318741
Genome Res. 2007 Jan;17(1):50-60
pubmed: 17090662
J Infect Dis. 2008 Feb 1;197(3):449-56
pubmed: 18199030
BMC Res Notes. 2012 Jan 20;5:53
pubmed: 22264291
Clin Microbiol Infect. 2007 Oct;13 Suppl 3:1-46
pubmed: 17716294
J Med Microbiol. 2017 Nov;66(11):1684-1687
pubmed: 29022544
J Clin Microbiol. 2011 Aug;49(8):2844-53
pubmed: 21653758
G3 (Bethesda). 2014 Nov 05;5(1):9-19
pubmed: 25378473
Nat Genet. 2012 Mar 11;44(4):413-9, S1
pubmed: 22406642
mBio. 2011 May 03;2(3):e00045-11
pubmed: 21540364
J Clin Microbiol. 2015 Jul;53(7):2172-9
pubmed: 25926497
PLoS One. 2011 Feb 11;6(2):e16971
pubmed: 21347295
Sex Transm Infect. 2016 Jun;92(4):299-304
pubmed: 26487754

Auteurs

Chloe Manning (C)

Department of Molecular Microbiology, Division of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Colette O'Neill (C)

Department of Molecular Microbiology, Division of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Ian N Clarke (IN)

Department of Molecular Microbiology, Division of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Monica Rebec (M)

Department of Microbiology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, United Kingdom.

Penelope R Cliff (PR)

Department of Infection Sciences, St Thomas' Hospital, London, United Kingdom.

Peter Marsh (P)

Public Health England, Porton Down, Salisbury, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH